GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (XSGO:ABBVCL) » Definitions » Enterprise Value

AbbVie (XSGO:ABBVCL) Enterprise Value : CLP358,954,939 Mil (As of Nov. 13, 2024)


View and export this data going back to 2024. Start your Free Trial

What is AbbVie Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, AbbVie's Enterprise Value is CLP358,954,939 Mil. AbbVie's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was CLP8,613,398 Mil. Therefore, AbbVie's EV-to-EBIT ratio for today is 41.67.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, AbbVie's Enterprise Value is CLP358,954,939 Mil. AbbVie's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was CLP15,911,259 Mil. Therefore, AbbVie's EV-to-EBITDA ratio for today is 22.56.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, AbbVie's Enterprise Value is CLP358,954,939 Mil. AbbVie's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was CLP48,477,532 Mil. Therefore, AbbVie's EV-to-Revenue ratio for today is 7.40.


AbbVie Enterprise Value Historical Data

The historical data trend for AbbVie's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Enterprise Value Chart

AbbVie Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AbbVie Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 379,332,039.46

Competitive Comparison of AbbVie's Enterprise Value

For the Drug Manufacturers - General subindustry, AbbVie's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Enterprise Value distribution charts can be found below:

* The bar in red indicates where AbbVie's Enterprise Value falls into.



AbbVie Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

AbbVie's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

AbbVie's Enterprise Value for the quarter that ended in Sep. 2024 is calculated as

Enterprise Value (Q: Sep. 2024 )
=Market Cap+Preferred Stock+Long-Term Debt & Capital Lease Obligation
=323609023+0+51075430.735
+Short-Term Debt & Capital Lease Obligation+Minority Interest-Cash, Cash Equivalents, Marketable Securities
+10972981.325+34045.049-6359440.649
=379,332,039

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbbVie  (XSGO:ABBVCL) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

AbbVie's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=358954939.131/8613397.512
=41.67

AbbVie's current Enterprise Value is CLP358,954,939 Mil.
AbbVie's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CLP8,613,398 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

AbbVie's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=358954939.131/15911259.395
=22.56

AbbVie's current Enterprise Value is CLP358,954,939 Mil.
AbbVie's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CLP15,911,259 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

AbbVie's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=358954939.131/48477531.578
=7.40

AbbVie's current Enterprise Value is CLP358,954,939 Mil.
AbbVie's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CLP48,477,532 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbbVie Enterprise Value Related Terms

Thank you for viewing the detailed overview of AbbVie's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie Business Description

Comparable Companies
Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

AbbVie Headlines

No Headlines